, in Immunology | www.frontiersin.org, p.541, 2018.

, in children with diffuse connective tissue diseases, Autoimmunity, 1990.

P. Schur and J. Sandson, Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus, New England Journal of Medicine, vol.278, issue.10, pp.533-541, 1968.
DOI : 10.1056/NEJM196803072781004

P. Alba, L. Bento, M. Cuadrado, Y. Karim, M. Tungekar et al.,

. Anti-dsdna, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis, Ann Rheum Dis, vol.62, issue.6, pp.556-60, 2003.

M. Homma, T. Mimori, Y. Takeda, H. Akama, T. Yoshida et al., Autoantibodies to the Sm antigen: immunological approach to clinical aspects of systemic lupus erythematosus, J Rheumatol, vol.14, pp.188-93, 1987.

J. Yang, Z. Xu, M. Sui, J. Han, L. Sun et al., Co-Positivity for Anti-dsDNA, -Nucleosome and -Histone Antibodies in Lupus Nephritis Is Indicative of High Serum Levels and Severe Nephropathy, PLOS ONE, vol.15, issue.2, 2015.
DOI : 10.1371/journal.pone.0140441.s004

G. Sardeto, L. Simas, T. Skare, R. Nisihara, and S. Utiyama, Antinucleosome in systemic lupus erythematosus. A study in a Brazilian population, Clinical Rheumatology, vol.18, issue.3, pp.553-559, 2012.
DOI : 10.1177/0961203308096255

N. Bizzaro, D. Villalta, D. Giavarina, and R. Tozzoli, Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis, Autoimmunity Reviews, vol.12, issue.2, pp.97-106, 2012.
DOI : 10.1016/j.autrev.2012.07.002

S. Saisoong, S. Eiam-ong, and O. Hanvivatvong, Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients, Clin Exp Rheumatol, vol.24, issue.1, pp.51-59, 2006.

R. Licht, M. Van-bruggen, B. Oppers-walgreen, T. Rijke, and J. Berden, Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: Effects of disease progression and lipopolysaccharide administration, 6<1320::AID-ART224>3.0.CO, pp.1320-1350, 2001.
DOI : 10.1038/33169

Z. Amoura, S. Koutouzov, H. Chabre, P. Cacoub, I. Amoura et al., Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus, 1<76::AID-ANR10>3.0.CO, pp.76-8410, 2000.
DOI : 10.1002/art.1780150206

M. Sui, M. Sui, Q. Lin, Z. Xu, X. Han et al., Simultaneous Positivity for Anti-DNA, Anti-Nucleosome and Anti-Histone Antibodies is a Marker for More Severe Lupus Nephritis, Journal of Clinical Immunology, vol.349, issue.16, pp.378-87, 2013.
DOI : 10.1056/NEJMoa021933

DOI : 10.1093/rheumatology/35.2.129

E. Benito-garcia, P. Schur, and R. Lahita, Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-Sm and anti-RNP antibody tests, Arthritis Care & Research, vol.11, issue.Suppl, pp.1030-1074, 2004.
DOI : 10.1191/0961203302lu158oa

A. Flechsig, T. Rose, F. Barkhudarova, R. Strauss, J. Klotsche et al., What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3, Clin Exp Rheumatol, vol.35, issue.4, pp.598-606, 2017.

H. Jaekel, T. Klopsch, B. Benkenstein, N. Grobe, A. Baldauf et al., Reactivities to the Sm Autoantigenic Complex and the Synthetic SmD1-aa83???119 Peptide in Systemic Lupus Erythematosus and other Autoimmune Diseases, Journal of Autoimmunity, vol.17, issue.4, pp.347-540545, 2001.
DOI : 10.1006/jaut.2001.0545

S. Ahn, B. Yoo, J. Song, Y. Park, S. Lee et al., Anti-Sm is associated with the early poor outcome of lupus nephritis, International Journal of Rheumatic Diseases, vol.30, issue.7, pp.897-902, 2016.
DOI : 10.1007/BF02231577

J. Ishizaki, K. Saito, M. Nawata, Y. Mizuno, M. Tokunaga et al., Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus, Rheumatology, vol.15, issue.1, pp.405-417, 2015.
DOI : 10.1186/ar4189

W. Habets, M. Hoet, P. Sillekens, D. Rooij, D. Van-de-putte et al., Detection of autoantibodies in a quantitative immunoassay using recombinant ribonucleoprotein antigens, Clin Exp Immunol, vol.76, issue.2, pp.172-179, 1989.

P. Gulko, J. Reveille, W. Koopman, S. Burgard, A. Bartolucci et al., Survival impact of autoantibodies in systemic lupus erythematosus, J Rheumatol, vol.21, issue.2, pp.224-232, 1994.

B. Kurien and R. Scofield, Autoantibody Determination in the Diagnosis of Systemic Lupus Erythematosus, Scandinavian Journal of Immunology, vol.332, issue.3, pp.227-262, 2006.
DOI : 10.1097/01.smj.0000171073.07875.c5

C. Vedove, D. Giglio, M. Schena, D. Girolomoni, and G. , Drug-induced lupus erythematosus, Archives of Dermatological Research, vol.167, issue.Supplement, pp.99-105, 2009.
DOI : 10.4049/jimmunol.167.12.6821

R. Rubin and S. Waga, Antihistone antibodies in systemic lupus erythematosus, J Rheumatol, vol.14, pp.118-144, 1987.

X. Sun, J. Shi, L. Han, Y. Su, and Z. Li, Anti???histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus, Journal of Clinical Laboratory Analysis, vol.42, issue.4, pp.271-278, 2008.
DOI : 10.1172/JCI105574

A. Van-rijthoven, J. Bijlsma, M. Canninga-van-dijk, R. Derksen, and J. Van-roon, Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level, Rheumatology, vol.45, issue.10, pp.1317-1326, 2006.
DOI : 10.1093/rheumatology/kel227

P. Gisondi and G. Girolomoni, Biologic therapies in psoriasis: A new therapeutic approach, Autoimmunity Reviews, vol.6, issue.8, pp.515-524, 2007.
DOI : 10.1016/j.autrev.2006.12.002

J. Harley, R. Scofield, and M. Reichlin, Anti-Ro in Sjögren's syndrome and systemic lupus erythematosus, Rheum Dis Clin North Am, vol.18, issue.2, pp.337-58, 1992.

M. Tikly, S. Burgin, P. Mohanlal, A. Bellingan, and J. George, Autoantibodies in black South Africans with systemic lupus erythematosus: Spectrum and clinical associations, Clinical Rheumatology, vol.54, issue.3, pp.261-266, 1996.
DOI : 10.1002/art.1780360219

G. Riemekasten and B. Hahn, Key autoantigens in SLE, Rheumatology, vol.44, issue.8, pp.975-82, 2005.
DOI : 10.3109/08916939508993358

URL : https://academic.oup.com/rheumatology/article-pdf/44/8/975/9448004/keh688.pdf

B. Kurien, J. Newland, C. Paczkowski, K. Moore, and R. Scofield, Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen, Clinical and Experimental Immunology, vol.97, issue.1, pp.209-226, 2000.
DOI : 10.7326/0003-4819-97-5-664

F. Vanoni, S. Lava, E. Fossali, R. Cavalli, G. Simonetti et al., Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review, Clinical Reviews in Allergy & Immunology, vol.176, issue.Suppl 2, pp.469-76, 2017.
DOI : 10.1007/s00431-017-2987-8

J. Buyon and R. Clancy, Neonatal Lupus: Basic Research and Clinical Perspectives, Rheumatic Disease Clinics of North America, vol.31, issue.2, pp.299-313, 2005.
DOI : 10.1016/j.rdc.2005.01.010

L. Lee, The clinical spectrum of neonatal lupus, Archives of Dermatological Research, vol.40, issue.1, pp.107-117, 2009.
DOI : 10.7326/0003-4819-120-7-199404010-00003

A. Zuppa, R. Riccardi, S. Frezza, F. Gallini, R. Luciano et al., Neonatal lupus: Follow-up in infants with anti -SSA/Ro antibodies and review of the literature, Autoimmunity Reviews, vol.16, issue.4, pp.427-459, 2017.
DOI : 10.1016/j.autrev.2017.02.010

R. Tunks, M. Clowse, S. Miller, L. Brancazio, and P. Barker, Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents, American Journal of Obstetrics and Gynecology, vol.208, issue.1, 2013.
DOI : 10.1016/j.ajog.2012.09.020

P. Izmirly, N. Costedoat-chalumeau, C. Pisoni, M. Khamashta, M. Kim et al., Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus, Circulation, vol.126, issue.1, pp.76-82, 2012.
DOI : 10.1161/CIRCULATIONAHA.111.089268

L. Rao, G. Liu, C. Li, Y. Li, Z. Wang et al., Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus, Experimental and Therapeutic Medicine, vol.5, issue.6, pp.1710-1714, 2013.
DOI : 10.3892/etm.2013.1051

P. Lazzerini, M. Acampa, F. Guideri, P. Capecchi, V. Campanella et al., Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases, Arthritis & Rheumatism, vol.39, issue.4, pp.1248-52, 2004.
DOI : 10.1016/S0735-1097(02)01852-1

P. Lazzerini, P. Capecchi, M. Acampa, G. Morozzi, F. Bellisai et al., Anti-Ro/SSA-associated corrected QT interval prolongation in adults: The role of antibody level and specificity, Arthritis Care & Research, vol.48, issue.10, pp.1463-70, 2011.
DOI : 10.1093/rheumatology/kep145

URL : http://onlinelibrary.wiley.com/doi/10.1002/acr.20540/pdf

P. Lazzerini, P. Capecchi, F. Guideri, F. Bellisai, E. Selvi et al., Comparison of frequency of complex ventricular arrhythmias in patients Frontiers in Immunology | www.frontiersin, p.541, 2018.

, SSA and connective tissue disease, Am J Cardiol, vol.100, issue.6, pp.1029-1063, 2007.

M. Pickering, M. Botto, P. Taylor, P. Lachmann, and M. Walport, Systemic Lupus Erythematosus, Complement Deficiency, and Apoptosis, Adv Immunol, vol.76, issue.01, pp.227-324, 2000.
DOI : 10.1016/S0065-2776(01)76021-X

C. Siegert, M. Daha, A. Swaak, E. Van-der-voort, and F. Breedveld, The Relationship between Serum Titers of Autoantibodies to C1q and Age in the General Population and in Patients with Systemic Lupus Erythematosus, Clinical Immunology and Immunopathology, vol.67, issue.3, pp.204-213, 1993.
DOI : 10.1006/clin.1993.1066

M. Trendelenburg, M. Lopez-trascasa, E. Potlukova, S. Moll, S. Regenass et al., High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis, Nephrology Dialysis Transplantation, vol.21, issue.11, pp.3115-3136, 2006.
DOI : 10.1093/ndt/gfl436

C. Siegert, M. Daha, C. Halma, E. Van-der-voort, and F. Breedveld, IgG and IgA autoantibodies to C1q in systemic and renal diseases, Clin Exp Rheumatol, vol.10, issue.1, pp.19-23, 1992.

R. Sinico, A. Radice, M. Ikehata, G. Giammarresi, C. Corace et al.,

, Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance, Ann N Y Acad Sci, vol.1050, pp.193-200, 2005.

C. Siegert, M. Daha, M. Westedt, E. Van-der-voort, and F. Breedveld, IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus, J Rheumatol, vol.18, issue.2, pp.230-234, 1991.

I. Gunnarsson, J. Rönnelid, Y. Huang, S. Rogberg, B. Nilsson et al., Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus, Rheumatology, vol.36, issue.1, pp.32-39, 1997.
DOI : 10.1093/rheumatology/36.1.32

G. Moroni, M. Trendelenburg, D. Papa, N. Quaglini, S. Raschi et al., Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis, American Journal of Kidney Diseases, vol.37, issue.3, pp.490-498, 2001.
DOI : 10.1053/ajkd.2001.22071

A. Orbai, L. Truedsson, G. Sturfelt, O. Nived, H. Fang et al., Anti-C1q antibodies in systemic lupus erythematosus, Lupus, vol.48, issue.1, pp.42-51, 2015.
DOI : 10.1006/clin.1993.1066

I. Coremans, P. Spronk, H. Bootsma, M. Daha, E. Van-der-voort et al., Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus, American Journal of Kidney Diseases, vol.26, issue.4, pp.595-601, 1995.
DOI : 10.1016/0272-6386(95)90595-2

C. Siegert, M. Daha, C. Tseng, I. Coremans, L. Van-es et al., Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus., Annals of the Rheumatic Diseases, vol.52, issue.12, pp.851-857, 1993.
DOI : 10.1136/ard.52.12.851

C. Siegert, M. Kazatchkine, A. Sjöholm, R. Würzner, M. Loos et al., Autoantibodies against C1q: view on clinical relevance and pathogenic roles, Clinical and Experimental Immunology, vol.11, issue.1, 1999.
DOI : 10.1007/BF02918613

V. Frémeaux-bacchi, L. Noël, and J. Schifferli, No lupus nephritis in the absence of antiC1q autoantibodies?, Nephrology Dialysis Transplantation, vol.17, issue.12, pp.2041-2044, 2002.
DOI : 10.1093/ndt/17.12.2041

M. Jachiet, B. Flageul, A. Deroux, L. Quellec, A. Maurier et al., The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-Seven Patients, Arthritis & Rheumatology, vol.73, issue.2, pp.527-561, 2015.
DOI : 10.1016/0091-6749(84)90518-9

E. Bonfa and K. Elkon, Clinical and serologic associations of the antiribosomal P protein antibody, Arthritis & Rheumatism, vol.81, issue.8, pp.981-986, 1986.
DOI : 10.1042/bj1230865

A. Ghirardello, L. Caponi, F. Franceschini, S. Zampieri, M. Quinzanini et al., Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays, Journal of Autoimmunity, vol.19, issue.1-2, pp.71-78, 2002.
DOI : 10.1006/jaut.2002.0595

A. Borchers, C. Aoki, S. Naguwa, C. Keen, Y. Shoenfeld et al., Neuropsychiatric features of systemic lupus erythematosus, Autoimmunity Reviews, vol.4, issue.6, pp.329-373, 2005.
DOI : 10.1016/j.autrev.2005.01.008

T. Eber, J. Chapman, and Y. Shoenfeld, Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?, Lupus, vol.22, issue.8, pp.571-576, 2005.
DOI : 10.1093/rheumatology/41.12.1357

T. Sato, T. Uchiumi, T. Ozawa, M. Kikuchi, M. Nakano et al., Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease, J Rheumatol, vol.18, issue.11, pp.1681-1685, 1991.

M. Reichlin, Autoantibodies to the ribosomal P proteins in systemic lupus erythematosus, Clinical and Experimental Medicine, vol.6, issue.2, pp.49-52, 2006.
DOI : 10.1007/s10238-006-0094-7

Y. Mei, P. Wang, C. Jiang, T. Wang, L. Chen et al., Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus, Clinical Rheumatology, vol.27, issue.2, pp.703-710, 2018.
DOI : 10.1002/jcla.21543

C. Mok, S. Tang, C. To, and M. Petri, Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups, Arthritis & Rheumatism, vol.52, issue.9, pp.2774-82, 2005.
DOI : 10.7326/0003-4819-128-9-199805010-00006

W. Wilson, A. Gharavi, T. Koike, M. Lockshin, D. Branch et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, 7<1309::AID-ANR1>3.0.CO, pp.1309-1320, 1999.
DOI : 10.1191/096120398678919624

M. Abreu, A. Danowski, D. Wahl, M. Amigo, M. Tektonidou et al., The relevance of ???non-criteria??? clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features, Autoimmunity Reviews, vol.14, issue.5, pp.401-415, 2015.
DOI : 10.1016/j.autrev.2015.01.002

G. Ruiz-irastorza, M. Egurbide, J. Ugalde, and C. Aguirre, High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus, Archives of Internal Medicine, vol.164, issue.1, pp.77-82, 2004.
DOI : 10.1001/archinte.164.1.77

URL : http://archinte.jamanetwork.com/data/journals/intemed/5469/ioi20852.pdf

A. Danowski, M. De-azevedo, J. De-souza-papi, and M. Petri, Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus, The Journal of Rheumatology, vol.36, issue.6, pp.1195-1204, 2009.
DOI : 10.3899/jrheum.081194

J. Lee, S. Naguwa, G. Cheema, and M. Gershwin, Revisiting Libman???Sacks Endocarditis: A Historical Review and Update, Clinical Reviews in Allergy & Immunology, vol.82, issue.2-3, pp.126-156, 2009.
DOI : 10.1590/S0066-782X2004000400009

S. Zuily, V. Regnault, C. Selton-suty, V. Eschwège, J. Bruntz et al., Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: Meta-Analysis of Echocardiographic Studies, Circulation, vol.124, issue.2, pp.215-239, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.028522

M. Petri, Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort, Lupus, vol.22, issue.13, pp.170-175, 2000.
DOI : 10.1016/0167-5273(90)90294-F

S. Zuily, V. Domingues, C. Suty-selton, V. Eschwège, L. Bertoletti et al., Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis, Autoimmunity Reviews, vol.16, issue.6, pp.576-86, 2017.
DOI : 10.1016/j.autrev.2017.04.003

S. Sciascia, G. Sanna, V. Murru, D. Roccatello, M. Khamashta et al., GAPSS: the Global Anti-Phospholipid Syndrome Score, Rheumatology, vol.39, issue.9, pp.1397-403, 2013.
DOI : 10.3899/jrheum.120073

URL : https://academic.oup.com/rheumatology/article-pdf/52/8/1397/5065260/kes388.pdf

W. Pereira, E. Reiche, A. Kallaur, and D. Kaimen-maciel, Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review, Journal of the Neurological Sciences, vol.355, issue.1-2, pp.7-17, 2015.
DOI : 10.1016/j.jns.2015.05.034

A. Dellavance, R. Alvarenga, S. Rodrigues, F. Kok, A. De-souza et al., Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases, European Journal of Neurology, vol.28, issue.2, pp.248-52, 2012.
DOI : 10.1007/s00296-008-0611-y

H. Li, Y. Wang, Q. Xu, A. Zhang, H. Zhou et al., Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis, Journal of Neurology, vol.417, issue.1???2, pp.2293-304, 2015.
DOI : 10.1016/j.cca.2012.12.008

J. Park, J. Hwang, J. Min, B. Kim, E. Kang et al., Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder, Journal of the Neurological Sciences, vol.348, issue.1-2, pp.132-137, 2015.
DOI : 10.1016/j.jns.2014.11.020

H. Alexopoulos, E. Kampylafka, P. Fouka, I. Tatouli, S. Akrivou et al., Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease, Journal of Neuroimmunology, vol.289, pp.8-11, 2015.
DOI : 10.1016/j.jneuroim.2015.10.007

Y. Long, W. Qiu, Z. Lu, J. Bao, A. Wu et al., Aquaporin 4 Antibodies in the Cerebrospinal Fluid Are Helpful in Diagnosing Chinese Patients with Neuromyelitis Optica, Neuroimmunomodulation, vol.66, issue.2, pp.96-102, 2012.
DOI : 10.1002/ana.21802

C. Shiboski, S. Shiboski, R. Seror, L. Criswell, M. Labetoulle et al., 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj??gren's syndrome, Annals of the Rheumatic Diseases, vol.46, issue.1, pp.9-16, 2016.
DOI : 10.3109/08916934.2012.732131

J. Mulli and A. Cruchaud, Immunoreactivity to Nuclear Antigens in Systemic Lupus Erythematosus with or without Nephritis, and in Other Connective Tissue Diseases, with Particular Reference to the RNA-Protein Antigen, International Archives of Allergy and Immunology, vol.53, issue.3, pp.279-89, 1977.
DOI : 10.1159/000231763

G. Sulcebe and K. Morcka, Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases, Clin Exp Rheumatol, vol.10, issue.3, pp.255-61, 1992.

P. Schur, D. Deangelis, and J. Jackson, Immunological detection of nucleic acids and antibodies to nucleic acids and nuclear antigens by counterimmunoelectrophoresis, Clin Exp Immunol, vol.17, issue.1, pp.209-227, 1974.

E. Theander, R. Jonsson, B. Sjöström, K. Brokstad, P. Olsson et al., Prediction of Sj??gren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling, Arthritis & Rheumatology, vol.69, issue.9, pp.2427-2463, 2015.
DOI : 10.1136/ard.2009.110619

F. Skopouli, U. Dafni, J. Ioannidis, and H. Moutsopoulos, Clinical evolution, and morbidity and mortalityof primary Sj??gren's syndrome, Seminars in Arthritis and Rheumatism, vol.29, issue.5, pp.296-304, 2000.
DOI : 10.1016/S0049-0172(00)80016-5

Y. Zhao, Y. Li, L. Wang, X. Li, C. Huang et al., Primary Sj??gren Syndrome in Han Chinese, Medicine, vol.94, issue.16, pp.667-677, 2015.
DOI : 10.1097/MD.0000000000000667

A. Fauchais, C. Martel, G. Gondran, M. Lambert, D. Launay et al., Immunological profile in primary Sj??gren syndrome, Autoimmunity Reviews, vol.9, issue.9, pp.595-604, 2010.
DOI : 10.1016/j.autrev.2010.05.004

N. Nardi, P. Brito-zerón, M. Ramos-casals, S. Aguiló, R. Cervera et al., Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sj??gren's syndrome, Clinical Rheumatology, vol.362, issue.Suppl, pp.341-347, 2006.
DOI : 10.1097/00005792-198207000-00004

A. Baer, M. Demarco, M. Shiboski, S. Lam, M. Challacombe et al., The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sj??gren's syndrome, Annals of the Rheumatic Diseases, vol.46, issue.8, pp.1557-61, 2015.
DOI : 10.1002/art.10407

L. Quartuccio, C. Baldini, E. Bartoloni, R. Priori, F. Carubbi et al., Anti-SSA/SSB-negative Sj??gren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution, Autoimmunity Reviews, vol.14, issue.11, pp.1019-1041, 2015.
DOI : 10.1016/j.autrev.2015.07.002

A. Ambrosi, S. Sonesson, and M. Wahren-herlenius, Molecular mechanisms of congenital heart block, Experimental Cell Research, vol.325, issue.1, 2014.
DOI : 10.1016/j.yexcr.2014.01.003

A. Brucato, M. Frassi, F. Franceschini, R. Cimaz, D. Faden et al., Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women, 8<1832::AID-ART320>3.0.CO, pp.1832-1837, 2001.
DOI : 10.1002/1529-0131(200005)43:5<1049::AID-ANR13>3.0.CO;2-X

S. Salomonsson, S. Sonesson, L. Ottosson, S. Muhallab, T. Olsson et al., Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block, The Journal of Experimental Medicine, vol.142, issue.1, pp.11-18, 2005.
DOI : 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9

URL : http://jem.rupress.org/content/jem/201/1/11.full.pdf

V. Bournia and P. Vlachoyiannopoulos, Subgroups of Sj??gren syndrome patients according to serological profiles, Journal of Autoimmunity, vol.39, issue.1-2, pp.15-26, 2012.
DOI : 10.1016/j.jaut.2012.03.001

T. Maruyama, I. Saito, Y. Hayashi, E. Kompfner, R. Fox et al., Molecular Analysis of the Human Autoantibody Response to ??-Fodrin in Sj??gren's Syndrome Reveals Novel Apoptosis-Induced Specificity, The American Journal of Pathology, vol.165, issue.1, pp.53-61, 2004.
DOI : 10.1016/S0002-9440(10)63274-9

Q. Qin, H. Wang, H. Wang, Y. Huang, H. Li et al., Diagnostic accuracy of anti-alpha-fodrin antibodies for primary Sj??gren's syndrome, Modern Rheumatology, vol.36, issue.9, pp.793-800, 2013.
DOI : 10.1111/j.1365-2222.2006.02550.x

Q. Hu, D. Wang, and W. Chen, The accuracy of the anti-??-fodrin antibody test for diagnosis of Sj??gren's syndrome: A meta-analysis, Clinical Biochemistry, vol.46, issue.15, pp.1372-1378, 2013.
DOI : 10.1016/j.clinbiochem.2013.04.020

G. Nordmark, F. Rorsman, L. Rönnblom, S. Cajander, M. Taussig et al., Autoantibodies to alpha-fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay, Clin Exp Rheumatol, vol.21, issue.1, pp.49-56, 2003.

H. Locht, R. Pelck, and R. Manthorpe, Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sjögren's syndrome, J Rheumatol, vol.35, issue.5, pp.845-854, 2008.

G. Hernández-molina, C. Nuñez-alvarez, C. Avila-casado, L. Llorente, C. Hernández-hernández et al., Usefulness of IgA Anti-??-fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies as Substitute Immunological Criterion in Sjogren Syndrome with Negative Anti-SSA/SSB Antibodies, The Journal of Rheumatology, vol.43, issue.10, pp.1852-1859, 2016.
DOI : 10.3899/jrheum.151315

F. Van-den-hoogen, D. Khanna, J. Fransen, S. Johnson, M. Baron et al., 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Annals of the Rheumatic Diseases, vol.62, issue.(Suppl), pp.2737-2784, 2013.
DOI : 10.1002/art.27580

G. Salazar, S. Assassi, F. Wigley, L. Hummers, J. Varga et al., Antinuclear antibody-negative systemic sclerosis, Seminars in Arthritis and Rheumatism, vol.44, issue.6, pp.680-686, 2015.
DOI : 10.1016/j.semarthrit.2014.11.006

URL : http://europepmc.org/articles/pmc4447614?pdf=render

D. Schneeberger, A. Tyndall, J. Kay, K. Søndergaard, P. Carreira et al., Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database, Rheumatology, vol.68, issue.4, pp.560-567, 2013.
DOI : 10.1007/s00393-008-0401-7

URL : https://academic.oup.com/rheumatology/article-pdf/52/3/560/5032184/kes315.pdf

C. Liaskos, E. Marou, T. Simopoulou, M. Barmakoudi, G. Efthymiou et al., Disease-related autoantibody profile in patients with systemic sclerosis, Autoimmunity, vol.33, issue.7, pp.414-435, 2017.
DOI : 10.1186/s13075-015-0573-x

I. Heijnen, C. Foocharoen, B. Bannert, P. Carreira, R. Caporali et al., Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR groupbased study, Clin Exp Rheumatol, vol.31, issue.2, pp.96-102, 2013.

R. Mierau, P. Moinzadeh, G. Riemekasten, I. Melchers, M. Meurer et al., Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features, Arthritis Research & Therapy, vol.13, issue.5, pp.10-3495, 1186.
DOI : 10.1007/s004120050219

Y. Hamaguchi, M. Hasegawa, M. Fujimoto, T. Matsushita, K. Komura et al., The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis, British Journal of Dermatology, vol.133, issue.3, pp.487-95, 2008.
DOI : 10.7326/0003-4819-133-8-200010170-00010

J. Reveille and D. Solomon, Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies, Arthritis & Rheumatism, vol.43, issue.3, pp.399-412, 2003.
DOI : 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.11113/pdf

A. Dellavance, C. Gallindo, M. Soares, N. Da-silva, R. Mortara et al., Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern, Rheumatology, vol.98, issue.19, pp.632-639, 2009.
DOI : 10.1073/pnas.191321998

URL : https://academic.oup.com/rheumatology/article-pdf/48/6/632/5064079/kep070.pdf

M. Jarzabek-chorzelska, M. Blaszczyk, S. Jablonska, T. Chorzelski, V. Kumar et al., Scl 70 antibody???a specific marker of systemic sclerosis, British Journal of Dermatology, vol.23, issue.4, pp.393-401, 1986.
DOI : 10.1001/archderm.119.7.560

S. Graf, P. Hakendorf, S. Lester, K. Patterson, J. Walker et al., South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome, International Journal of Rheumatic Diseases, vol.60, issue.4, 2012.
DOI : 10.1002/art.24409

U. Walker, A. Tyndall, L. Czirják, C. Denton, D. Farge-bancel et al., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database, Annals of the Rheumatic Diseases, vol.66, issue.6
DOI : 10.1136/ard.2006.062901

, Ann Rheum Dis, vol.66, issue.6, pp.754-63, 2007.

P. Hu, N. Fertig, T. Medsger, and T. Wright, Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis, Arthritis & Rheumatism, vol.84, issue.5, pp.1363-73, 2003.
DOI : 10.1006/clin.1997.4362

M. Kuwana, J. Kaburaki, T. Mimori, Y. Kawakami, and T. Tojo, Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis, 5<1074::AID-ANR18>3.0.CO, pp.1074-84, 2000.
DOI : 10.1002/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E

M. Kuwana, J. Kaburaki, Y. Okano, T. Tojo, and M. Homma, Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis, Arthritis & Rheumatism, vol.35, issue.1, pp.75-83, 1994.
DOI : 10.1097/00005792-198403000-00003

G. Mitri, M. Lucas, N. Fertig, V. Steen, and T. Medsger, A comparison between anti-Th/To??? and anticentromere antibody???positive systemic sclerosis patients with limited cutaneous involvement, Arthritis & Rheumatism, vol.48, issue.1, pp.203-212, 2003.
DOI : 10.1002/art.10760

M. Santiago, M. Baron, M. Hudson, R. Burlingame, and M. Fritzler, Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA, J Rheumatol, vol.34, issue.7, pp.1528-1562, 2007.

V. Sobanski, L. Dauchet, G. Lefèvre, M. Lambert, S. Morell-dubois et al., Prevalence of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta-Analysis, Arthritis & Rheumatology, vol.92, issue.Suppl 1, pp.407-424, 2014.
DOI : 10.1097/MD.0b013e31829be125

T. Phan, A. Cass, A. Gillin, P. Trew, N. Fertig et al., Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma, J Rheumatol, vol.26, issue.11, pp.2489-92, 1999.

P. Moinzadeh, C. Fonseca, M. Hellmich, A. Shah, C. Chighizola et al., Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma, Arthritis Research & Therapy, vol.16, issue.1, pp.10-1186, 2014.
DOI : 10.1080/03009740902758875

URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar4486?site=arthritis-research.biomedcentral.com

M. Lazzaroni, I. Cavazzana, E. Colombo, R. Dobrota, J. Hernandez et al., Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening, The Journal of Rheumatology, vol.44, issue.5, pp.639-686, 2017.
DOI : 10.3899/jrheum.160817

A. Herrick, S. Peytrignet, M. Lunt, X. Pan, R. Hesselstrand et al., Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study, Annals of the Rheumatic Diseases, vol.77, issue.4, pp.10-1136, 2018.
DOI : 10.1136/annrheumdis-2017-211912.supp5

A. Ceribelli, M. Krzyszczak, Y. Li, S. Ross, J. Chan et al., Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase i reactivity and nucleolar staining, Arthritis Research & Therapy, vol.13, issue.4, pp.10-3422, 1186.
DOI : 10.1111/j.1365-2230.2006.02092.x

A. Shah, A. Rosen, L. Hummers, F. Wigley, and L. Casciola-rosen, Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies, Arthritis & Rheumatism, vol.3, issue.9, pp.2787-95, 2010.
DOI : 10.1016/0167-4781(95)00171-9

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.27549/pdf

M. Kuwana, J. Kaburaki, T. Mimori, T. Tojo, and M. Homma, Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis., Journal of Clinical Investigation, vol.91, issue.4, pp.1399-404, 1993.
DOI : 10.1172/JCI116343

Y. Hamaguchi, M. Kodera, T. Matsushita, M. Hasegawa, Y. Inaba et al., Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti-RNA Polymerase III Autoantibodies, Arthritis & Rheumatology, vol.32, issue.4, pp.1045-52, 2015.
DOI : 10.1002/anr.1780320911

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38994/pdf

M. Mahler, R. Raijmakers, C. Dähnrich, M. Blüthner, and M. Fritzler, Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen, Arthritis Research & Therapy, vol.7, issue.3, pp.704-717, 1455.
DOI : 10.1186/ar1729

K. Hanke, C. Brückner, C. Dähnrich, D. Huscher, L. Komorowski et al., Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients, Arthritis Research & Therapy, vol.11, issue.1, p.10, 1186.
DOI : 10.1186/ar2614

URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar2614?site=arthritis-research.biomedcentral.com

M. Wodkowski, M. Hudson, S. Proudman, J. Walker, W. Stevens et al., Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects, Autoimmunity, vol.35, issue.8, pp.542-51, 2015.
DOI : 10.1186/s13075-015-0573-x

B. Rozman, S. Cucnik, S. Sodin-semrl, L. Czirják, C. Varjú et al., Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study, Annals of the Rheumatic Diseases, vol.67, issue.9, pp.1282-6073981, 2007.
DOI : 10.1136/ard.2007.073981

S. Hoa, M. Hudson, Y. Troyanov, S. Proudman, J. Walker et al., Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects, Medicine, vol.95, issue.35, pp.95-4713, 2016.
DOI : 10.1097/MD.0000000000004713

URL : http://pdfs.journals.lww.com/md-journal/2016/08300/Single_specificity_anti_Ku_antibodies_in_an.68.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1504749048791;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzddFRrD2hcIwdDP9eSnSkfs80IcAqYqdta1Zm+65IrmaA=;hash|/wvxohCTPz1UsvbDzKgVpg==

D. Charlton, M. Laffoon, T. Medsger, and R. Domsic, Long-term survival and follow-up of anti-Th/to antibody positive systemic sclerosis patients, Arthritis Rheumatol, vol.69, pp.1-4426, 2017.

V. Sobanski, J. Giovannelli, B. Lynch, B. Schreiber, S. Nihtyanova et al., Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension, Arthritis & Rheumatology, vol.64, issue.Suppl 86, pp.484-93, 2016.
DOI : 10.1111/j.1365-3083.2006.01770.x

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.39432/pdf

H. Ihn, K. Yamane, N. Yazawa, M. Kubo, M. Fujimoto et al., Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis, Clinical and Experimental Immunology, vol.38, issue.2, pp.383-390, 1999.
DOI : 10.1016/0092-8674(84)90551-8

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2249.1999.00961.x/pdf

V. Tormey, C. Bunn, C. Denton, and C. Black, Anti???fibrillarin antibodies in systemic sclerosis, Rheumatology, vol.40, issue.10, pp.1157-62, 2001.
DOI : 10.1002/art.1780310207

URL : https://academic.oup.com/rheumatology/article-pdf/40/10/1157/18094746/401157.pdf

R. Aggarwal, M. Lucas, N. Fertig, C. Oddis, and T. Medsger, Anti-U3 RNP autoantibodies in systemic sclerosis, Arthritis & Rheumatism, vol.48, issue.4, pp.1112-1120, 2009.
DOI : 10.1056/NEJM197502132920706

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.24409/pdf

F. Arnett, J. Reveille, R. Goldstein, K. Pollard, K. Leaird et al., Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis, Arthritis & Rheumatism, vol.83, issue.7, pp.1151-60, 1996.
DOI : 10.7326/0003-4819-119-10-199311150-00007

R. Sharif, M. Fritzler, M. Mayes, E. Gonzalez, T. Mcnearney et al., Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis, The Journal of Rheumatology, vol.38, issue.8, pp.1622-1652, 2011.
DOI : 10.3899/jrheum.110071

J. Schulte-pelkum, M. Fritzler, and M. Mahler, Latest update on the Ro/SS-A autoantibody system, Autoimmunity Reviews, vol.8, issue.7, pp.632-639, 2009.
DOI : 10.1016/j.autrev.2009.02.010

T. Fujii, T. Mimori, and M. Akizuki, Detection of autoantibodies to nucleolar transcription factor NOR 90/hubf in sera of patients with rheumatic diseases, by recombinant autoantigen???based assays, Arthritis & Rheumatism, vol.140, issue.8, pp.1313-1321, 1996.
DOI : 10.1002/art.1780390808

G. Morozzi, F. Bellisai, I. Fineschi, F. Scaccia, G. Pucci et al., Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients, Autoimmunity Highlights, vol.36, issue.1, pp.29-33, 2011.
DOI : 10.3899/jrheum.080806

R. Hesselstrand, A. Scheja, G. Shen, A. Wiik, and A. Akesson, The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis, Rheumatology, vol.42, issue.4, pp.534-574, 2003.
DOI : 10.1093/rheumatology/keg170

G. Laustriat, A. Ruyssen-witrand, A. Constantin, T. Barnetche, D. Adoue et al., Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning, Joint Bone Spine, vol.85, issue.2, pp.147-53, 2017.
DOI : 10.1016/j.jbspin.2017.11.006

M. Koenig, M. Fritzler, I. Targoff, Y. Troyanov, and J. Senécal, Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes, Arthritis Research & Therapy, vol.9, issue.4, pp.10-1186, 2007.
DOI : 10.1186/ar2276

URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar2276?site=arthritis-research.biomedcentral.com

Y. Troyanov, I. Targoff, J. Tremblay, J. Goulet, R. Y. Senécal et al., Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies, Medicine, vol.84, issue.4, pp.231-280, 2005.
DOI : 10.1097/01.md.0000173991.74008.b0

URL : http://pdfs.journals.lww.com/md-journal/2005/07000/Novel_Classification_of_Idiopathic_Inflammatory.5.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1503454446568;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzddFRrD2hcIwdDP9eSnSkfs3Yq/IxEDZo0f4KRzkCU9Ds=;hash|+8auJX2Rt3eV8xg+yXGkXw==

J. Hoogendijk, A. Amato, B. Lecky, E. Choy, I. Lundberg et al., 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis The Netherlands, Neuromuscul Disord, vol.14, issue.5, pp.10-12337, 2003.

T. Lloyd, A. Mammen, A. Amato, M. Weiss, M. Needham et al., Evaluation and construction of diagnostic criteria for inclusion body myositis, Neurology, vol.83, issue.5, pp.426-459, 2014.
DOI : 10.1212/WNL.0000000000000642

URL : http://europepmc.org/articles/pmc4132572?pdf=render

J. Lega, N. Fabien, Q. Reynaud, I. Durieu, S. Durupt et al., The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome, Autoimmunity Reviews, vol.13, issue.9, pp.883-91, 2014.
DOI : 10.1016/j.autrev.2014.03.004

G. Connors, L. Christopher-stine, C. Oddis, and S. Danoff, Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies, Chest, vol.138, issue.6, pp.1464-74, 2010.
DOI : 10.1378/chest.10-0180

H. Yoshifuji, T. Fujii, S. Kobayashi, Y. Imura, Y. Fujita et al., Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies, Autoimmunity, vol.3, issue.4, pp.233-411008916930600622884, 1080.
DOI : 10.1007/s11926-001-0039-9

I. Pinal-fernandez, M. Casal-dominguez, J. Huapaya, J. Albayda, J. Paik et al., A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies, Rheumatology, vol.108, issue.11, pp.999-1007, 2017.
DOI : 10.1016/j.rmed.2014.09.003

B. Hervier, H. Devilliers, R. Stanciu, A. Meyer, Y. Uzunhan et al., Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity, Autoimmunity Reviews, vol.12, issue.2, pp.210-217, 2012.
DOI : 10.1016/j.autrev.2012.06.006

I. Marie, S. Josse, O. Decaux, S. Dominique, E. Diot et al., Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome, Autoimmunity Reviews, vol.11, issue.10, pp.739-784, 2012.
DOI : 10.1016/j.autrev.2012.01.006

URL : https://hal.archives-ouvertes.fr/hal-00872923

K. Stone, C. Oddis, N. Fertig, Y. Katsumata, M. Lucas et al., Anti???Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy, Arthritis & Rheumatism, vol.169, issue.9, pp.3125-3156, 2007.
DOI : 10.4049/jimmunol.169.12.7127

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.22865/pdf

M. Milone, Diagnosis and Management of Immune-Mediated Myopathies, Mayo Clinic Proceedings, vol.92, issue.5, pp.826-863, 2017.
DOI : 10.1016/j.mayocp.2016.12.025

C. Kassardjian, V. Lennon, N. Alfugham, M. Mahler, and M. Milone, Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy, JAMA Neurology, vol.72, issue.9, pp.996-1003, 2015.
DOI : 10.1001/jamaneurol.2015.1207

URL : http://archneur.jamanetwork.com/data/journals/neur/934389/noi150031.pdf

L. Arouche-delaperche, Y. Allenbach, D. Amelin, C. Preusse, V. Mouly et al., Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies, Annals of Neurology, vol.1592, issue.suppl 1, pp.538-586, 2017.
DOI : 10.1016/S0167-4889(02)00318-X

Y. Allenbach, L. Arouche-delaperche, C. Preusse, H. Radbruch, G. Butler-browne et al., myopathies, Neurology, vol.90, issue.6, pp.507-524, 2018.
DOI : 10.1212/WNL.0000000000004923

URL : https://hal.archives-ouvertes.fr/hal-01518320

Y. Watanabe, A. Uruha, S. Suzuki, J. Nakahara, K. Hamanaka et al., Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.10, pp.1038-1082, 2016.
DOI : 10.1002/art.34673

L. Christopher-stine, L. Casciola-rosen, G. Hong, T. Chung, A. Corse et al., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis & Rheumatism, vol.41, issue.9, pp.2757-66, 2010.
DOI : 10.1212/WNL.41.6.936

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.27572/pdf

J. Werner, L. Christopher-stine, S. Ghazarian, K. Pak, J. Kus et al., Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy, Arthritis & Rheumatism, vol.41, issue.12, pp.4087-93, 2012.
DOI : 10.1002/acr.20035

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.34673/pdf

C. Ashton, R. Junckerstorff, C. Bundell, P. Hollingsworth, and M. Needham, Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective, Neuromuscular Disorders, vol.26, issue.11, pp.734-774, 2016.
DOI : 10.1016/j.nmd.2016.08.013

URL : http://researchrepository.murdoch.edu.au/id/eprint/33231/1/Needham1.pdf

A. Mammen, Statin-Associated Autoimmune Myopathy, New England Journal of Medicine, vol.374, issue.7, pp.664-673, 2016.
DOI : 10.1056/NEJMra1515161

O. Benveniste, L. Drouot, F. Jouen, J. Charuel, C. Bloch-queyrat et al., Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy, Arthritis & Rheumatism, vol.247, issue.7, pp.1961-71, 2011.
DOI : 10.1007/s004150050585

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.30344/pdf

I. Pinal-fernandez, C. Parks, J. Werner, J. Albayda, J. Paik et al., Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle, Arthritis Care & Research, vol.24, issue.11, pp.263-70, 2017.
DOI : 10.1097/BOR.0b013e328358bd85

D. Fiorentino, L. Chung, L. Christopher-stine, L. Zaba, S. Li et al., Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1??, Arthritis & Rheumatism, vol.146, issue.Suppl, pp.2954-62, 2013.
DOI : 10.1001/archdermatol.2009.328

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38093/pdf

K. Kaji, M. Fujimoto, M. Hasegawa, M. Kondo, Y. Saito et al., Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy, Rheumatology, vol.46, issue.1, pp.25-33, 2007.
DOI : 10.1093/rheumatology/kel161

E. Trallero-araguás, J. Rodrigo-pendás, A. Selva-o-'callaghan, X. Martínez-gómez, X. Bosch et al., Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis, Arthritis & Rheumatism, vol.49, issue.Suppl, pp.523-555, 2012.
DOI : 10.1093/rheumatology/keq153

N. Mugii, M. Hasegawa, T. Matsushita, Y. Hamaguchi, S. Oohata et al., Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies, PLOS ONE, vol.27, issue.5, 2016.
DOI : 10.1371/journal.pone.0154746.s002

URL : https://doi.org/10.1371/journal.pone.0154746

A. Ceribelli, M. Fredi, M. Taraborelli, I. Cavazzana, F. Franceschini et al., Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis, Arthritis Research & Therapy, vol.14, issue.2, pp.97-107, 2012.
DOI : 10.1186/ar3822

URL : https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar3822?site=arthritis-research.biomedcentral.com

H. Gunawardena, L. Wedderburn, H. Chinoy, Z. Betteridge, J. North et al., Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis, Arthritis & Rheumatism, vol.103, issue.6, pp.1807-1821, 2009.
DOI : 10.1056/NEJM197502202920807

URL : http://europepmc.org/articles/pmc2701555?pdf=render

G. Espada, M. Cocco, J. Fertig, N. Oddis, and C. , Clinical and Serologic Characterization of an Argentine Pediatric Myositis Cohort: Identification of a Novel Autoantibody (anti-MJ) to a 142-kDa Protein, The Journal of Rheumatology, vol.36, issue.11, pp.2547-51, 2009.
DOI : 10.3899/jrheum.090461

D. Fiorentino, L. Chung, J. Zwerner, A. Rosen, and L. Casciola-rosen, The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A??retrospective study, Journal of the American Academy of Dermatology, vol.65, issue.1, pp.25-34, 2011.
DOI : 10.1016/j.jaad.2010.09.016

URL : http://europepmc.org/articles/pmc3167687?pdf=render

Z. Chen, M. Cao, M. Plana, J. Liang, H. Cai et al., Utility of Anti-Melanoma Differentiation-Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta-Analysis, Arthritis Care & Research, vol.64, issue.8, pp.1316-1340, 2013.
DOI : 10.1002/art.34657

L. Zhang, G. Wu, D. Gao, G. Liu, L. Pan et al., Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis, PLOS ONE, vol.8, issue.5, 2016.
DOI : 10.1371/journal.pone.0155381.s004

URL : https://doi.org/10.1371/journal.pone.0155381

R. Nakashima, Y. Imura, S. Kobayashi, N. Yukawa, H. Yoshifuji et al., The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody, Rheumatology, vol.50, issue.3, pp.433-473, 2010.
DOI : 10.1002/pbc.21423

URL : https://academic.oup.com/rheumatology/article-pdf/49/3/433/17386711/kep375.pdf

Y. Muro, K. Sugiura, K. Hoshino, and M. Akiyama, Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission, Rheumatology, vol.81, issue.8, pp.800-804, 2012.
DOI : 10.1128/JVI.01360-06

URL : https://academic.oup.com/rheumatology/article-pdf/51/5/800/5112341/ker408.pdf

T. Gono, S. Sato, Y. Kawaguchi, M. Kuwana, M. Hanaoka et al., Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis, Rheumatology, vol.29, issue.11, pp.1563-70, 2012.
DOI : 10.1002/art.1780291109

E. Tarricone, A. Ghirardello, M. Rampudda, N. Bassi, L. Punzi et al., Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort, Journal of Immunological Methods, vol.384, issue.1-2, pp.128-162, 2012.
DOI : 10.1016/j.jim.2012.07.019

Z. Betteridge, H. Gunawardena, H. Chinoy, J. North, W. Ollier et al., Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1621-5097162, 2008.
DOI : 10.1136/ard.2008.097162

Y. Muro, K. Sugiura, and M. Akiyama, Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients, Autoimmunity, vol.43, issue.4, pp.279-84, 2013.
DOI : 10.1016/j.molcel.2011.05.020

E. Kang, R. Nakashima, T. Mimori, J. Kim, Y. Lee et al., Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis, BMC Musculoskeletal Disorders, vol.49, issue.1, pp.223-233, 2010.
DOI : 10.1093/rheumatology/keq153

URL : https://bmcmusculoskeletdisord.biomedcentral.com/track/pdf/10.1186/1471-2474-11-223?site=bmcmusculoskeletdisord.biomedcentral.com

M. Petri, M. Satoh, B. Martin-marquez, R. Vargas-ramírez, L. Jara et al., Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara, Arthritis Research & Therapy, vol.15, issue.2, pp.48-58, 2013.
DOI : 10.1186/ar3739

K. Schmidt and J. Schmidt, Inclusion body myositis, Current Opinion in Rheumatology, vol.29, issue.6, pp.632-640, 2017.
DOI : 10.1097/BOR.0000000000000436

M. Salajegheh, T. Lam, and S. Greenberg, Autoantibodies against a 43 KDa muscle protein in inclusion body myositis, PLoS One, vol.6, issue.5, 2011.
DOI : 10.1371/journal.pone.0020266

URL : https://doi.org/10.1371/journal.pone.0020266

M. Herbert, J. Stammen-vogelzangs, M. Verbeek, A. Rietveld, I. Lundberg et al., Disease specificity of autoantibodies to cytosolic 5???-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases, Annals of the Rheumatic Diseases, vol.6, issue.4, pp.696-701, 2016.
DOI : 10.1371/journal.pone.0020266

URL : http://europepmc.org/articles/pmc4699257?pdf=render

O. Benveniste, W. Stenzel, and Y. Allenbach, Advances in serological diagnostics of inflammatory myopathies, Current Opinion in Neurology, vol.29, issue.5, pp.662-73, 2016.
DOI : 10.1097/WCO.0000000000000376

J. Smolen, D. Aletaha, and I. Mcinnes, Rheumatoid arthritis, The Lancet, vol.388, issue.10055, pp.2023-2061, 2016.
DOI : 10.1016/S0140-6736(16)30173-8

URL : https://hal.archives-ouvertes.fr/hal-01558198

M. Kapetanovic, L. Larsson, L. Truedsson, G. Sturfelt, T. Saxne et al., Predictors of infusion reactions during infliximab treatment in patients with arthritis, Arthritis Res Ther, vol.8, issue.4, pp.10-1186, 2006.

N. Yukawa, T. Fujii, S. Kondo-ishikawa, H. Yoshifuji, D. Kawabata et al., Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study, Arthritis Research & Therapy, vol.13, issue.6, pp.10-1186, 2011.
DOI : 10.1136/ard.2009.121491

M. Othman, W. Ghazali, W. Hamid, K. Wong, and N. Yahya, Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor, Saudi Medical Journal, vol.38, issue.9, pp.934-975, 2017.
DOI : 10.15537/smj.2017.9.20841

URL : https://www.smj.org.sa/index.php/smj/article/download/smj.2017.9.20841/10433

F. Arnett, S. Edworthy, D. Bloch, D. Mcshane, J. Fries et al., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis & Rheumatism, vol.143, issue.3, pp.315-339, 1988.
DOI : 10.1002/art.1780310302

D. Aletaha, T. Neogi, A. Silman, J. Funovits, D. Felson et al., 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, vol.61, issue.Suppl 31, pp.2569-81, 2010.
DOI : 10.7326/0003-4819-124-8-199604150-00001

URL : https://hal.archives-ouvertes.fr/hal-01557559

X. Jiang, T. Frisell, J. Askling, E. Karlson, L. Klareskog et al., To What Extent Is the Familial Risk of Rheumatoid Arthritis Explained by Established Rheumatoid Arthritis Risk Factors?, Arthritis & Rheumatology, vol.4, issue.2, pp.352-62, 2015.
DOI : 10.1371/journal.pone.0007969

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.38927/pdf

T. Frisell, K. Hellgren, L. Alfredsson, S. Raychaudhuri, L. Klareskog et al., Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden, Annals of the Rheumatic Diseases, vol.45, issue.1
DOI : 10.1038/ng.2711

, Ann Rheum Dis, vol.75, issue.1, pp.183-192, 2016.

E. Franklin, H. Holman, H. Muller-eberhard, and H. Kunkel, AN UNUSUAL PROTEIN COMPONENT OF HIGH MOLECULAR WEIGHT IN THE SERUM OF CERTAIN PATIENTS WITH RHEUMATOID ARTHRITIS, Journal of Experimental Medicine, vol.105, issue.5, pp.425-463, 1957.
DOI : 10.1084/jem.105.5.425

P. Taylor, J. Gartemann, J. Hsieh, and J. Creeden, A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis, Autoimmune Dis, pp.2011-815038, 2011.

T. Jónsson, H. Thorsteinsson, S. Arinbjarnarson, J. Thorsteinsson, and H. Valdimarsson, Clinical implications of IgA rheumatoid factor subclasses., Annals of the Rheumatic Diseases, vol.54, issue.7, pp.578-81, 1995.
DOI : 10.1136/ard.54.7.578

E. Tan and J. Smolen, Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor, The Journal of Experimental Medicine, vol.12, issue.10, pp.1937-50, 2016.
DOI : 10.1155/2015/236451

URL : http://jem.rupress.org/content/213/10/1937.full.pdf

S. Farid, G. Azizi, and A. Mirshafiey, Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis, International Journal of Rheumatic Diseases, vol.50, issue.2, pp.379-86, 2013.
DOI : 10.1002/art.20018

URL : http://onlinelibrary.wiley.com/doi/10.1111/1756-185X.12129/pdf

B. Young, R. Mallya, R. Leslie, C. Clark, and T. Hamblin, Anti-keratin antibodies in rheumatoid arthritis., BMJ, vol.2, issue.6182, pp.97-106, 1979.
DOI : 10.1136/bmj.2.6182.97

URL : http://static.www.bmj.com/content/bmj/2/6182/97.full.pdf

R. Aggarwal, K. Liao, R. Nair, S. Ringold, and K. Costenbader, Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis, Arthritis Care & Research, vol.33, issue.11, pp.611472-83, 2009.
DOI : 10.1136/ard.2005.045229

URL : http://onlinelibrary.wiley.com/doi/10.1002/art.24827/pdf

G. Schellekens, B. De-jong, F. Van-den-hoogen, L. Van-de-putte, and W. Van-venrooij, Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies., Journal of Clinical Investigation, vol.101, issue.1, pp.273-81, 1316.
DOI : 10.1172/JCI1316

URL : http://www.jci.org/articles/view/1316/files/pdf

J. Payet, C. Goulvestre, L. Bialé, J. Avouac, J. Wipff et al., Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients, The Journal of Rheumatology, vol.41, issue.12, pp.2395-402, 2014.
DOI : 10.3899/jrheum.131375

O. Meyer, C. Labarre, M. Dougados, P. Goupille, A. Cantagrel et al., Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage, Annals of the Rheumatic Diseases, vol.62, issue.2, pp.120-126, 2003.
DOI : 10.1136/ard.62.2.120

URL : http://ard.bmj.com/content/annrheumdis/62/2/120.full.pdf

S. Syversen, P. Gaarder, G. Goll, S. Ødegård, E. Haavardsholm et al., High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study, Annals of the Rheumatic Diseases, vol.67, issue.2, pp.212-7068247, 2006.
DOI : 10.1136/ard.2006.068247

M. Nielen, D. Van-schaardenburg, H. Reesink, R. Van-de-stadt, I. Van-der-horst-bruinsma et al., Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors, Arthritis & Rheumatism, vol.44, issue.2, pp.380-386, 2004.
DOI : 10.1136/ard.44.8.519

J. Salmon, J. Perotin, J. Morel, M. Dramé, A. Cantagrel et al., Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data, Rheumatology, vol.68, issue.1, pp.134-143, 2018.
DOI : 10.1002/art.39595